1130. Low Risk of Pneumocystis jiroveci Pneumonia in Patients With Waldenstrom’s Macroglobulinemia on Ibrutinib

BACKGROUND: Ibrutinib is a Bruton’s tyrosine kinase inhibitor that is FDA approved for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom’s macroglobulinemia (WM). Fungal infections including Pneumocystis jiroveci pneumonia (PCP) are in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusztos, Amanda E, Cheng, Matthew P, Gustine, Joshua N, Dubeau, Toni E, Woolley, Ann E, Hammond, Sarah P, Baden, Lindsey R, Castillo, Jorge J, Issa, Nicolas C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255451/
http://dx.doi.org/10.1093/ofid/ofy210.963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255451/
http://dx.doi.org/10.1093/ofid/ofy210.963

Ejemplares similares